9-Fluorenol
9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC50 value of 9 μM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo[1].
Product Specifications
CAS Number
[1689-64-1]
Product Name Alternative
9-Hydroxyfluorene
UNSPSC
12352005
Hazard Statement
H302
Target
Dopamine Receptor; Drug Metabolite
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/9-fluorenol.html
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1C2=CC=CC=C2C3=CC=CC=C31
Molecular Formula
C13H10O
Molecular Weight
182.22
Precautions
H302
References & Citations
[1]Dunn D, et al. Wake promoting agents: search for next generation modafinil, lessons learned: part III. Bioorg Med Chem Lett. 2012 Jun 1;22 (11) :3751-3.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
128991-HRP 100 µL
LAMA5 (Laminin Subunit alpha-5, Laminin-10 Subunit alpha, Laminin-11 Subunit alpha, Laminin-15 Subunit alpha, KIAA0533, KIAA1907) (HRP)
Ask
View Details MBS6486871-01 0.2 mL
MARK3, CT (MAP/microtubule Affinity-regulating Kinase 3, Cdc25C-associated Protein Kinase 1, cTAK1, C-TAK1, ELKL Motif Kinase 2, EMK2, EMK-2, KP78, Protein Kinase STK10, Ser/Thr Protein Kinase PAR-1, PAR1A, Par-1a, Serine/threonine-protein Kinase p78) (Bi
Ask
View Details 
MBS6486871-02 5x 0.2 mL
MARK3, CT (MAP/microtubule Affinity-regulating Kinase 3, Cdc25C-associated Protein Kinase 1, cTAK1, C-TAK1, ELKL Motif Kinase 2, EMK2, EMK-2, KP78, Protein Kinase STK10, Ser/Thr Protein Kinase PAR-1, PAR1A, Par-1a, Serine/threonine-protein Kinase p78) (Bi
Ask
View Details 